
DERM Stock Forecast & Price Target
DERM Analyst Ratings
Bulls say
Journey Medical Corp has demonstrated significant growth in payer access, expanding coverage from approximately 30% of commercial lives to around 65% within a two-month period, which translates to over 100 million lives enhanced by their product offerings. Additionally, prescriber adoption has seen substantial increases, rising from about 660 in the first quarter to over 1,800 by the second quarter, indicating strong market traction and acceptance of the company's products. Furthermore, the enduring brand value of key products like Accutane fosters consumer retention and market share stability, further supporting a positive outlook for the company's financial prospects.
Bears say
Journey Medical Corp has experienced a significant decline in prescription volume for its key product, Accutane, with first-quarter 2025 prescriptions falling to approximately 66,000 from 93,000 in the same period of 2024, indicating potential challenges in market demand. Additionally, the company's future earnings before interest, taxes, depreciation, and amortization (EBITDA) may be adversely affected by slower-than-anticipated uptake of its new product, Emrosi, coupled with potential reimbursement barriers from payers. There are also multiple risks associated with its operations, including competitive pressures from both branded and generic treatments, regulatory uncertainties, and the possibility of increased cash burn that could impact financial stability going forward.
This aggregate rating is based on analysts' research of Journey Medical Corp and is not a guaranteed prediction by Public.com or investment advice.
DERM Analyst Forecast & Price Prediction
Start investing in DERM
Order type
Buy in
Order amount
Est. shares
0 shares